TY - CHAP M1 - Book, Section TI - Cardiometabolic Disease: Insulin Resistance, Obesity, and the Metabolic Syndrome A1 - Garvey, W. Timothy A1 - Mechanick, Jeffrey I. A2 - Fuster, Valentin A2 - Narula, Jagat A2 - Vaishnava, Prashant A2 - Leon, Martin B. A2 - Callans, David J. A2 - Rumsfeld, John A2 - Poppas, Athena PY - 2022 T2 - Fuster and Hurst's The Heart, 15e AB - Chapter SummaryThis chapter discusses the pathophysiology and treatment of cardiometabolic disease and obesity. Insulin resistance is at the core of the pathophysiology of cardiometabolic disease and can give rise to metabolic syndrome, prediabetes, and non-alcoholic fatty liver disease (NAFLD) (see Fuster and Hurst’s Central Illustration). Patients with insulin resistance, metabolic syndrome, and/or prediabetes have accelerated atherogenesis and increased risk for cardiovascular disease (CVD). Prediabetes and NAFLD can progress to type 2 diabetes and non-alcoholic steatohepatitis (NASH), respectively; these conditions further amplify the progression of vascular disease and risk of CVD events. Obesity can exacerbate insulin resistance and promote cardiometabolic disease progression, but it can also exist independent of cardiometabolic disease. In the prevention and treatment of cardiometabolic disease, intervention should be early and encompass metabolic and vascular outcomes. Healthy meal plans, aerobic and resistance exercise, and aggressive surveillance and management of CVD risk factors are all warranted. A chronic care model for cardiometabolic disease should be an integral component of health-care systems. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2023/12/03 UR - accesscardiology.mhmedical.com/content.aspx?aid=1202441966 ER -